And that is a reasonable general framework pulled from the clinical trial protocol
FDA approval of semaglutide (2021) and tirzepatide (2023) for chronic weight management, the use of incretin-based therapies for obesity treatment has accelerated rapidly
Interactions with other medications Medication side effects : Some other medications can cause fatigue as a side effect
The dose-response data broke down as follows: 1mg dose: 8.7% average weight loss at 48 weeks 4mg dose: 15.2% average weight loss at 48 weeks 8mg dose: 21.1% average weight loss at 48 weeks 12mg dose: 24.2% average weight loss at 48 weeks Placebo: 2.1% average weight loss at 48 weeks The week-by-week progression told an equally compelling story
These data come from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 307 million patient records from 2,000 hospitals and more than 49,000 clinics from all 50 U.S
Adults with a BMI of 30 or higher, or 27 with a weight-related condition such as high blood pressure or sleep apnea, may qualify for weight loss treatment through Klinic
)
)
)
